Tag:

Biotech deals

Latest Headlines

Latest Headlines

Analysis: Big Pharma is backing out of more biotech deals

Anyone tracking drug development deals these days will already know that Big Pharma's trigger finger is getting increasingly itchy when it comes to killing unwanted or unsuccessful collaboration

Takeda pursues Nycomed with $12B-$14B buyout offer

The business press is buzzing this morning with word that Japan's acquisitive Takeda is in talks to buy Nycomed for up to $14 billion. Bloomberg broke the M&A story late last night, noting that

PBM chief says soaring biotech sector will inspire M&A blitz

Medco CEO David Snow keeps close tabs on the blockbuster drugs which are about to face generic competition. And the PBM chief has also done the math on biotech drugs, which will steadily swell from

Merrimack ropes back international rights to cancer drug in $220M pact

When Merrimack Pharmaceuticals bought out Hermes Biosciences near the end of 2009, it touted the prospects for the UCSF spinout's lead drug, MM-398, then in mid-stage studies for multiple cancer

INC snags Kendle's global CRO operations for $232M in cash

Determined to vault into the top tier of the global CRO business, INC Research has struck a deal to buy out Kendle ($KNDL) for $232 million in cash. The deal gives INC global Phase I-IV operations

Valeant CEO scanning biopharma horizon for fresh targets

Valeant Pharmaceuticals ($VRX) CEO Michael Pearson didn't take much time to get over the loss of Cephalon ($CEPH). Ever the hunter, Pearson tells Reuters that "time is the enemy." And right now the

Lilly, Medtronic partner on new approach to treating Parkinson's

Just a year-and-a-half after buying up promising new diagnostic technology for Parkinson's, Eli Lilly has signed up for a new collaboration with Medtronic that will marry its biologic approach to

SciClone strikes $105M deal to buy China's NovaMed

Lured by the booming Chinese pharmaceuticals market, Foster City, CA-based SciClone Pharmaceuticals ($SCLN) has struck a deal to buy Shanghai-based NovaMed Pharmaceuticals for $24.7 million in cash

Baxter nabs Prism's arrythmia drug in $338M buyout

Just months after gaining an FDA approval for ready-to-use IV formulations of its anti-arrhythmic agent Nexterone, Prism Pharmaceuticals has sealed a $338 million buyout deal with Baxter

Pfizer inks $210M orphan drug discovery pact with Zacharon

A little more than two years since it announced a $3.5 million Series A round, San Diego's Zacharon Pharmaceuticals has inked a $210 million discovery deal with Pfizer ($PFE) that will target new